R Paridaens
Overview
Explore the profile of R Paridaens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
143
Citations
1511
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Brouckaert O, Paridaens R, Floris G, Rakha E, Osborne K, Neven P
Ann Oncol
. 2012 Aug;
24(1):47-53.
PMID: 22847811
Steroid receptors have been around in the field of breast cancer for decades now. Still, controversy remains on how best to report steroid receptors. In this review, we will convince...
12.
Brouckaert O, Laenen A, Vanderhaegen J, Wildiers H, Leunen K, Amant F, et al.
Ann Oncol
. 2012 Apr;
23(10):2578-2584.
PMID: 22492698
Background: Many easily measurable and readily available factors are now established as being prognostic in primary operable breast cancer. We here applied the 2011 St Gallen surrogate definition for breast...
13.
Haest K, Kumar A, Van Calster B, Leunen K, Smeets A, Amant F, et al.
Ann Oncol
. 2011 Nov;
23(6):1449-54.
PMID: 22039079
Background: We studied the stellate ganglion block (SGB) recently suggested for the treatment of severe vasomotor symptoms and sleep disturbances in breast cancer survivors. Following an initial pilot study, which...
14.
Lintermans A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, Westhovens R, et al.
Ann Oncol
. 2011 Jan;
22(8):1763-9.
PMID: 21273342
Background: Our preliminary results showed that tenosynovial changes and decrease in grip strength are associated with the aromatase inhibitor-induced musculoskeletal syndrome (AIMSS). Here, we report the final results and assess...
15.
Van Belle V, Decock J, Hendrickx W, Brouckaert O, Pintens S, Moerman P, et al.
Patholog Res Int
. 2011 Jan;
2011:918408.
PMID: 21253502
Axillary lymph node involvement is an important prognostic factor for breast cancer survival but is confounded by the number of nodes examined. We compare the performance of the log odds...
16.
Smeets A, Daemen A, Vanden Bempt I, Gevaert O, Claes B, Wildiers H, et al.
Breast Cancer Res Treat
. 2010 Dec;
129(3):767-76.
PMID: 21116709
The aim of this study was to investigate whether lymph node involvement in breast cancer is influenced by gene or miRNA expression of the primary tumor. For this purpose, we...
17.
Wildiers H, Neven P, Christiaens M, Squifflet P, Amant F, Weltens C, et al.
Ann Oncol
. 2010 Aug;
22(3):588-594.
PMID: 20709813
Background: To evaluate capecitabine-docetaxel (XT), with trastuzumab (H) in human epidermal growth factor receptor 2 (HER2)-positive disease, in inoperable locally advanced breast cancer (LABC). Patients And Methods: Patients received up...
18.
Wildiers H, Fontaine C, Vuylsteke P, Martens M, Canon J, Wynendaele W, et al.
Breast Cancer Res Treat
. 2010 Jul;
123(2):463-9.
PMID: 20652398
The aim of this study is to test the hypothesis that antiangiogenic treatment with sunitinib consolidation can prolong remissions induced by taxane-based chemotherapy in women with metastatic breast cancer. The...
19.
Leyssens B, Wildiers H, Lobelle J, Gillis A, Paridaens R, Mombaerts I
Ann Oncol
. 2009 Jul;
21(2):419-423.
PMID: 19622592
Background: Dacryostenosis is a common side-effect of weekly docetaxel (Taxotere). We investigate the efficacy of eyedrops containing corticosteroids (CS) versus artificial tears (AT) in patients receiving weekly docetaxel in the...
20.
Dieudonne A, Lambrechts D, Claes B, Vandorpe T, Wildiers H, Timmerman D, et al.
Breast Cancer Res Treat
. 2009 Jul;
118(3):531-8.
PMID: 19597703
Retrospective studies suggest that single nucleotide polymorphisms in the cytochrome P450 2D6 (CYP2D6) gene predict reduced tamoxifen metabolism, better tolerance and worse treatment outcome. We hypothesized that women with this...